Chugai Pharmaceutical : Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)

About this update from Chugai Pharmaceutical Co., Ltd.

Zenyaku Kogyo Co., Ltd. Chugai Pharmaceutical Co., Ltd. Announcement of Termination of Co-Promotion of Rituxan ® in Japan (Anti-CD20 Monoclonal Antibody) TOKYO, April 9, 2026 -- Zenyaku Kogyo Co., Ltd. (Japanese-only website) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the termination of the co-promotion in Japan for Rituxan ® intravenous infusion 100 mg and 500 mg [generic name: rituximab (genetic recombination)] (hereafter, "Rituxan"), effective September 3, 2026. To date, Zenyaku Kogyo and Chugai have been conducting co-promotion and medical information activities for Rituxan. Following a review of future sales policy, Chugai's sales of Rituxan will end upon sell-out of its remaining inventory. Effective September 4, 2026, Zenyaku Kogyo will assume sole responsibility for the sales of Rituxan and the provision of medical information. Zenyaku Kogyo and Chugai will work together to ensure a smooth transfer of sales activities for Rituxan. During the transition period, both companies will continue, as they have to date, their efforts to ensure a stable supply, provide information aligned with medical needs, and promote the appropriate use of Rituxan. Trademarks used or mentioned in this release are protected by law.

View stock analysis, news, and events for Chugai Pharmaceutical Co., Ltd.